FDA estrogen guidances withdrawn
Executive Summary
FDA withdrawing final clinical trial guidance on estrogen/progestin therapy: "Guidance for Clinical Evaluation of Combination Estrogen/Progestin-Containing Drug Products Used for Hormone Replacement Therapy of Postmenopausal Women," agency says in Sept. 10 Federal Register notice. FDA is also pulling the draft labeling guidance "Labeling Guidance for Noncontraceptive Estrogen Drug Products: Prescribing Information for Healthcare Providers and Patient Labeling." The decision comes after the NIH Women's Health Initiative trial was halted due to an increased risk of breast cancer and cardiovascular events in patients on Wyeth's Prempro (1"The Pink Sheet" July 15, p. 11). FDA plans to hold a public meeting on the hormone therapy issue this fall (2"The Pink Sheet" Aug. 19, p. 11)...
You may also be interested in...
Estrogen Products Guidance To Be Revised; FDA Will Outline Plans In June
FDA will make significant changes to a 2003 FDL-1draft guidance on estrogen products and reissue a new draft
Wyeth Prempro Updated Label Submission Soon; HHS To Discuss WHI Results
Wyeth expects to submit updated Prempro labeling reflecting the results of the Women's Health Initiative study on use of the hormone replacement therapy soon, the company said
Prempro Cancer Risk Addressed In 550,000 Physician Letters, Label Review
Wyeth is sending letters to approximately 550,000 physicians as part of a Prempro risk management program to address risks associated with use of the hormone combination for cardiovascular disease and osteoporosis prevention